WHAT IS CLAIMED IS:

1. A hybrid antigen comprising at least one antigenic domain of an infectious agent or tumor antigen and a binding domain that non-covalently binds to a heat shock protein, and wherein the binding domain comprises Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:417), Phe Tyr Gln Leu Ala Leu Tyr Trp (SEQ ID NO:418), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:419).

2. The hybrid antigen of Claim 1 wherein a peptide linker separates the antigenic domain and the binding domain.

3. The hybrid antigen of Claim 1 wherein at least one of the antigenic domains is a T helper epitope.

4. A composition for inducing an immune response to an infectious agent or tumor antigen comprising at least one hybrid antigen of Claim 1.

5. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject at least one hybrid antigen of Claim 1.

6. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject a complex of:

(a) a hybrid antigen of Claim 1; and

(b) a heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

7. The method of claim 6 wherein the heat shock protein is a hsp70.

8. A method for treating an infectious disease or cancer comprising administering to a subject at least one hybrid antigen of Claim 1, wherein at least one antigenic domain is from the infectious disease or cancer.

9. A method for treating an infectious disease or cancer comprising administering to a subject a complex of:

(a) a hybrid antigen of Claim 1, wherein at least one antigenic domain is from the infectious disease or cancer; and

(b) a heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

10. The method of claim 9 wherein the heat shock protein is a hsp70.

11. A hybrid antigen consisting essentially of at least one antigenic domain of an infectious agent or tumor antigen, a binding domain that non-covalently binds to a heat shock protein, and a peptide linker separating the antigenic domain and the binding domain, and wherein the binding domain comprises Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:417), Phe Tyr Gln Leu Ala Leu Tyr Trp (SEQ ID NO:418), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:419).

12. The hybrid antigen of Claim 11 wherein at least one of the antigenic domains is a T helper epitope.

13. A composition for inducing an immune response to an infectious agent or tumor antigen comprising at least one hybrid antigen of Claim 11.

14. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject at least one hybrid antigen of Claim 11.

15. A method for inducing an immune response to an infectious agent or tumor antigen comprising administering to a subject a complex of:

(a) a hybrid antigen of Claim 11; and

(b) a heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

16. The method of claim 15 wherein the heat shock protein is a hsp70.

17. A method for treating an infectious disease or cancer comprising administering to a subject at least one hybrid antigen of Claim 11, wherein at least one antigenic domain is from the infectious disease or cancer.

18. A method for treating an infectious disease or cancer comprising administering to a subject a complex of:

(a) a hybrid antigen of Claim 1, wherein the antigenic domain is from the infectious disease or cancer; and

(b) a heat shock protein;

wherein the hybrid antigen and the heat shock protein are non-covalently bound.

19. The method of claim 18 wherein the heat shock protein is a hsp70.

20. A peptide that is Asn Leu Leu Arg Leu Thr Gly Trp (SEQ ID NO:417), Phe Tyr Gln Leu Ala Leu Tyr Trp (SEQ ID NO:418), or Arg Lys Leu Phe Phe Asn Leu Arg Trp (SEQ ID NO:419).